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ORIGINAL ARTICLE
Survival after CABG  better than predicted by EuroSCORE
and equal to the general population
KRISTIN V. T. ENGEBRETSEN2*, CHARLOTTE FRIIS2*, LEIV SANDVIK2,3 &
THEIS TØNNESSEN1,2
1Department of Cardiothoracic Surgery, Ulleva˚l University Hospital, Oslo, Norway, 2University of Oslo, Oslo, Norway, and
3Unit of Biostatistics and Epidemiology, Ulleva˚l University Hospital, Oslo, Norway.
Abstract
Objectives. Examine short- and intermediate-term survival after coronary artery bypass grafting (CABG) and compare this
to survival of the general population and to that predicted by EuroSCORE. Design. One thousand three hundred and fifty
one consecutive patients undergoing CABG were prospectively included. Survival status was ascertained through the
Norwegian National Registry. Results. Compared to the general population, no statistical significant difference in survival
was seen in operated patients. Overall mortality rate was 0.8% after 30 days, 2.8%, 4.0% and 7.1% at one, two and three
years, respectively. When patients were divided into four groups according to EuroSCORE, mortality increased significantly
with increasing score, as expected. However, EuroSCORE overestimated mortality. Conclusion. Patients operated with
CABG at our institution have similar survival as in the general Norwegian population. Although overestimating mortality by
almost five-fold, we found a strong association between EuroSCORE and short-time survival, and an association between
EuroSCORE and intermediate-term survival.
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programs
Given the high number of coronary artery bypass
grafting (CABG) procedures worldwide, mortality-
rate associated with the operation has a great impact
on society. Low mortality-rate has been considered
an important parameter suggesting high treatment-
quality. However, highly specialized centers operat-
ing more complicated cases will normally have a
higher mortality. A widely used method to predict
per- and postoperative 30-days mortality associated
with open heart surgery, is the EuroSCORE (1).
This score is based upon a cohort of 19 030
consecutive adult patients undergoing cardiac sur-
gery at 128 surgical centers in eight European states.
Univariate and logistic regression analyses were used
to identify significant preoperative risk factors pre-
dicting 30-days mortality. Comparison of Euro-
SCORE (i.e. predicted mortality) to actual 30-days
mortality will give an estimate of the quality of the
cardiac surgery performed in a specific institution.
Furthermore, this ratio might also, to a certain
degree, allow comparison between institutions. Ac-
cording to the registry of The Norwegian Associa-
tion for Cardiothoracic Surgery (2), 30-days
mortality after open heart surgery in Norway is
lower than predicted by EuroSCORE. There might
be several reasons for this. Increasing quality of the
heart-surgery over the last years, a different cohort of
patients compared to that originally used to calculate
EuroSCORE, might be some of the explanation.
In addition to short-term survival compared to
predicted mortality by EuroSCORE, intermediate-
and long-term survival of patients undergoing
CABG compared to that of the general population
is also of great importance. Comparing survival
between operated patients and the general popula-
tion in different age groups might help guiding
us in selecting patients for operation. Although this
has been performed earlier in other countries (35),
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life-expectancy might differ markedly between coun-
tries and within a country over time. Thus, a
continuous revision and report of such data gives
valuable information to the decision making clin-
ician.
The aim of the present study was, therefore, to
determine the short- and intermediate-term survival
among patients undergoing CABG at Ulleva˚l Uni-
versity Hospital (UUH) and to compare the actual
mortality to that predicted by EuroSCORE.
Furthermore, we wanted to examine whether Euro-
SCORE could predict mortality beyond 30 days. We
also wanted to compare survival of patients under-
going CABG surgery to that of the general popula-
tion in Norway.
Our study is based on a cohort of patients
operated consecutively at UUH from January 1,
2003 until December 31, 2006. Basic data of
patients were registered prospectively in the hospital
database and their survival status was established
through the Norwegian National Registry (6).
Materials and methods
One thousand three hundred and fifty one patients
operated consecutively for primary CABG, in the
time period from January 1, 2003 to December 31,
2006, were included in the study. Patients under-
going additional surgery to CABG were excluded
from the study. All patients were operated through a
median sternotomy as previously described (7).
Data, registered prospectively, were obtained from
the hospital database and from patient files. Hyper-
tension was defined as clinically recognized and
under medical treatment. Smoking was defined as
smoking until the month before operation.
The survival status as of December 31, 2006 was
established through the Norwegian National Regis-
try (6), and the collection of data was done at least
three months after this date to ensure that all deaths
of the study patients were registered. The endpoint
was death from any cause. To compare patient-
survival to the general population, patients were
divided into 3 groups. Group 1 included patients
from 059 years (n398), group 2 included patients
from 6069 years (n445) and group 3 included
patients above the age of 70 years (n493). Eleven
patients that had emigrated from the country and
not been observed after December 31, 2006, were
not included in the study as were four patients that
could not be identified in the National Registry.
Thus, a total of 1 336 patients underwent further
analysis.
The calculated EuroSCORE number for a specific
patient gives the additive percentage risk of dying
within 30 days of a heart operation (Appendix 1).
For example, an EuroSCORE of 1 predicts a one
percent risk of dying in hospital or within the first 30
postoperative days. Our patients were divided into
groups according to EuroSCORE as calculated by
Appendix 1. The groups were divided based on the
need to account for enough patients in each group to
make statistical analyses. Groups were defined as
follows: Group 1: (n325) EuroSCORE 1-2, group
2: (n386) EuroSCORE 3-4, group 3: (n277)
EuroSCORE 5-6 and group 4: (n177) Euro-
SCORE 7 and above.
Data concerning measurements of Ck-mb and
Troponin-T was retrieved from the patient database
at Ulleva˚l University Hospital. Serum levels of both
Ck-mb and Troponin-T were all measured by the
Department of Clinical Chemistry as previously
described (8). Ck-mb and Troponin-T values were
routinely measured preoperatively and 7 hours, 20
hours, and 44 hours postoperatively.
Statistical analysis
Data from continuous variables are presented as
mean and standard deviation, and data from binary
variables are presented as percentages. Adjusted and
unadjusted associations between background vari-
ables and mortality were investigated by means of
the proportional-hazards model (9). Results from
such analysis are presented as hazard rates (HR)
with 95% confidence intervals (CI). For a contin-
uous variable the presented HR may be interpreted
as the relative increase in mortality when the variable
increases one standard deviation. Thus, if HR for
creatinin equals 1.16, this implies that mortality
increases with 16% when creatinin increases by one
standard deviation. For a binary variable with score
‘yes’ or ‘no’, the presented HR may be interpreted as
the mortality in the ‘yes’ group divided by the
mortality in the ‘no’ group.
Kaplan-Meier curves were used to estimate mor-
tality after 30 days, and after 1, 2 and 3 years in our
CABG study. Data from Statistics Norway (6) were
used to estimate age-, gender- and time period-
matched mortality after 1, 2, and 3 years in the
general population of Norway.
In order to decide whether a mortality curve from
the CABG study differs significantly from a corre-
sponding mortality curve from the general popula-
tion, a standardized mortality rate with 95%
confidence interval was calculated.
The assumptions of the proportional-hazards
model were checked for each model, and found to
be adequately met. The models were computed with
the use of Statistical Package for the Social Sciences
(SPSS) version 14.0.






































Table I shows baseline characteristics of the patients
in our cohort. The mean age was 65 years and 19%
of the patients were women. Two hundred and forty
one of the patients were followed more than 3 years,
606 more than 2 years, 971 more than 1 year and 1
306 more than 30 days. Variables predicting mor-
tality in our patient cohort are shown in the table
with the corresponding HR and p-value.
Short- and intermediate-term survival
In Figure 1 the patient population is divided into
three groups according to age. We have compared
the survival of the operated patients to that of the
general Norwegian population in the same age group
as reported by the Norwegian National Statistical
Registry. In group 1, patients were from 059 years
old with a mean age of 53 years (356 men and 42
women). One year survival was 99.1%, two years
survival 99.1% and three years survival 97.2%. In
group 2 patients ranged from 60-69 years with a
mean age of 65 years (363 men and 82 women).
Group 2 showed a one year survival of 98.8%, two
years survival of 98.1% and three years survival of
95.6%. In group 3 the patients were from 70 years
and older with a mean age of 75 years (366 men and
127 women). Group 3 had a one year survival of
94.3%, two years survival of 91.6% and three years
survival of 86.2%. Compared to the general Norwe-
gian population, we did not find any statistical
significant different survival of operated patients at
one, two and three years. However, there was a
tendency in group 2 of a better survival in the patient
population. Thirty days mortality was 0% in group 1
and 2 and 2% in group 3. The overall mortality rate
in our cohort was 0.8% at 30 days, 2.8% at one year,
4.0% at two years, and 7.1% at three years.
EuroSCORE and mortality
The association between EuroSCORE and mortality
is shown in Figure 2. Although meant for prediction
of 30-days mortality, we have extended the predic-
tion up to three years. The patients were divided into
four groups. The first group (n325) included
those with EuroSCORE 1-2. They had a 30-days
mortality of 0%, one year mortality of 0.4%, two
years mortality 0.4% and three years mortality of
0.4%. We used the first group as reference and sat
HR as 1. The second group (n386) included
patients with EuroSCORE 34. They had a 30-
days mortality 0.8%, one year mortality of 2.0%, two
years mortality of 3.2% and three years mortality of
7.0%. Compared to the first group HR was 13
(CI 1-101, p0.012), i.e. mortality was significantly
higher in group 2 than in group 1. The third group
(n277) included patients with EuroSCORE 56.
Table I. Demographic and cardiac variables. Analyses are presented as hazard rates (HR) with 95% confidence intervals (CI). S.D.Stan-
dard deviation, NYHANew York Heart Association, COPDchronic obstructive pulmonary disease, EFejection fraction, CPB time
cardiopulmonary bypass time.
Variable p-value HR (95% CI)
Demographic variables
Age (mean9S.D.) 65.0910.0 B0.001 1.09 (1.06-1.13)
Female (%) 18.8 0.106 1.59 (0.912.77)
NYHA (mean9S.D.) 2.890.8 n.s. 0.94 (0.701.26)
COPD (%) 6.4 n.s 1.66 (0.723.86)
Renal failure (%) 1.3 B0.002 4.99 (1.8113.7)
Creatinin preop., mg/dl (mean9S.D.) 89.6953.0 B0.001 1.16 (1.071.25)
Creatinin 2 days postop., mg/dl (mean9S.D.) 86.0953.0 B0.001 1.28 (1.171.39)
EF (%, mean9S.D.) 60.2915.3 B0.002 0.69 (0.550.87)
Diabetes (%) 15.9 n.s. 1.17 (0.612.24)
Apoplexia cerebri (%) 19 n.s. 0.93 (0.136.67)
Emergency (%) 3.6 n.s. 1.28 (0.404.11)
CPB time, minutes (mean9S.D.) 75.5922.2 n.s. 1.12 (0.881.42)
EuroSCORE (mean9S.D.) 3.692.5 B0.001 1.33 (1.231.44)
Hypertension (%) 41.4 0.071 1.58 (0.962.60)
Smoking (%) 27.3 n.s. 1.21 (0.712.08)
Extracardiac arteriopathy (%) 9.4 B0.001 4.08 (2.367.07)
Cardiac variables
Unstable angina (%) 1.8 n.s. 1.49 (0.366.11)
Distal anastomosis (mean9S.D.) 3.190.9 n.s. 1.09 (0.831.44)
Previous myocardial infarction (%) 35.6 n.s. 1.35 (0.812.23)
Occlution time, minutes (mean9S.D.) 38.9913.6 n.s. 0.86 (0.771.25)
Ck-mb max (mean 9S.D.) 36.6938.4 0.002 1.22 (1.081.38)
Troponin-T max (mean9S.D.) 0.7490.9 B0.001 1.40 (1.291.53)




































They had a 30-days mortality of 1.1%, one year
mortality of 5.4%, two years mortality of 7.1% and
three years mortality of 10.3%. Compared to the first
group HR was 24 (CI 3-176, p0.002). The fourth
group (n177) included patients with EuroSCORE
7 and higher. The 30-days mortality was 2.3%, one
year mortality 6.7%, two years mortality 10.4% and
three years mortality was 18.3%. When compared to
the first group HR was 40 (CI 5-299, pB0.001).
Discussion
The present study shows that survival up to three
years postoperatively following CABG is at least as
high as in the general Norwegian population. A
tendency to higher survival was found in patients
between 60 and 69 years old. Thirty days mortality
was 0.8% in the present study whereas predicted
mortality according to EuroSCORE was 3.6%.
EuroSCORE might be used to predict mortality
also beyond 30 days postoperatively.
Our statistical analysis showed that age, EF,
preoperative renal failure, high levels of creatinine




















Gen. pop. 0-59 years
CABG 0-59 years
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Figure 1. Kaplan-Meier estimate of unadjusted survival showing 3 years survival after coronary artery bypass surgery. Survival curves for

























Figure 2. Kaplan-Meier mortality curve, showing mortality dur-
ing 3 years postoperative (postop.) follow-up according to Euro-
SCORE.




































age and gender, Ck-mb and Troponin-T are all
single variables that may be used to predict mortal-
ity. Myers and co-workers (10) evaluated 8221
patients operated by CABG in the Coronary Artery
Study (CASS) registry, with a mean follow-up of 15
years. Heavier weight, prior myocardial infarction,
diabetes, and smoking were all associated with
increased late mortality (3,10). Although the same
factors did not reach statistical significant in our
study, the tendency was still there. Surprisingly,
neither diabetes nor previous myocardial infarction
turned out to be statistical significant predictors of
survival during 3 years. It is, however, possible that
these factors will reach statistical significance if the
patients in our study had been followed for another
12 years. In our cohort we have not discriminated
between cardiac and non-cardiac death, since our
study was strictly designed to measure overall
survival. Herlitz and co-workers followed 2000
patients for 13 years after CABG and found that
the most frequent cause of death was heart failure
followed by myocardial infarction (11). Factors
found to be associated with increased risk of cardiac
death included high age, current smoking, history of
myocardial infarction, hypertension, and diabetes.
The present study shows that survival among
patients operated with CABG in our hospital is the
same, or even shows a tendency to be better, as in
the general Norwegian population. There might
be several reasons for this finding. Patients offered
an operation for coronary artery disease represents a
selected group fit enough to be eligible for a major
surgical procedure. Thus, especially in the older
patient groups, patients with severe co-morbidities
or cancer with short life-expectancy will not be
offered CABG. A lack of such patients in the cohort
operated with CABG compared to the prevalence of
such patients in the general Norwegian population
might in part explain the findings of the present
study. Another point is of course that patients in the
present study are treated for a potentially deadly
disease with a treatment (CABG) documented to
reduce mortality. In the general Norwegian popula-
tion there might be patients with asymptomatic
coronary artery disease or patients too sick to be
offered an operation which might increase mortality
in this specific group. However, if our patients are
followed for a longer period of time, the cardiovas-
cular disease might evolve and result in an unfavor-
able outcome for CABG patients compared to the
general population in a longer perspective.
Our study showed a strong association between
EuroSCORE and short-term survival. However,
EuroSCORE in our cohort of patients predicted
almost five times the mortality that was actually
found according to the National Registry (6). These
findings are in accordance with those recently
reported by Mølstad from the Feiring Clinic (12).
Several factors might explain this finding. Euro-
SCORE was established in a study analyzing patients
undergoing CABG in 1995 (1). First, most likely,
there has been an improved quality over the years
both regarding surgery, preoperative and postopera-
tive care. At our institution, specifically, we have
introduced an intermediate ward (‘‘step down’’)
between the postoperative unit and the regular
ward. This intermediate ward has a better surveil-
lance of the patients compared to a regular ward and
offers respiratory support by skilled personnel, such
as continuous positive airway pressure (CPAP),
when needed. Instead of being sent directly to a
regular ward the first postoperative day, patients will
normally stay 2-4 days in the intermediate ward
before being sent to the regular ward or to a local
hospital. It should also be noted that we have
dedicated anesthesiologists and operating nurses
allocated to our department only. Secondly, the
cohort of patients operated in Norway and in our
department might differ from that of the Euro-
SCORE study. There are obvious risk factors that
are not detected by the EuroSCORE system, such as
heavy calcification of the aorta and of the peripheral
coronary arteries. Moreover, EuroSCORE includes
both patients who dies within 30 days postopera-
tively and after 30 days but within the same hospital
stay. However, no registry in Norway allows us to
exactly register in hospital-mortality of patients
surviving the first 30 postoperative days, although
this is most likely a limited number of patients.
Another point is that the EuroSCORE itself might
reduce mortality in that it allows us to identify the
high risk patients before surgery and may contribute
to improvements in peroperative strategy and post-
operative care. The mortality rate increases at all the
different time-points in each EuroSCORE-group
suggesting an association between EuroSCORE
and intermediate-term survival. It should be noted,
however, that few patients were followed for as long
as three years. The limited number of patients in the
present study does not allow a multivariate analysis
with the same power as that performed in the
original EuroSCORE calculation. Thus, the associa-
tion between EuroSCORE and intermediate-term
survival needs to be confirmed in a larger cohort of
patients to be able to correlate intermediate-term
survival to the specific preoperative variables used in
the original EuroSCORE-calculation.
In conclusion, the present study shows that
survival up to three years postoperatively following
CABG is at least as high as in the general Norwegian
population. Thirty days mortality in our cohort
of patients was 0.8%, whereas that predicted by




































EuroSCORE was 3.6%. Nevertheless, our study
showed that EuroSCORE might also be used to
predict mortality beyond 30 days postoperatively.
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Age (per 5 years or part thereof over 60 years) 1
Sex female 1
Chronic pulmonary disease longterm use of bronchodilators or steroids for lung disease 1
Extracardiac arteriopathy any one or more of the following: claudication, carotid occlusion or 50%
stenosis, previous or planned intervention on the abdominal aorta, limb
arteries or carotids
2
Neurological dysfunction disease severely affecting ambulation or day-to-day functioning 2
Previous cardiac surgery requiring opening of the pericardium 3
Serum creatinine 200m micromol/L preoperatively 2
Active endocarditis patient still under antibiotic treatment for endocarditis at the time of surgery 3
Critical preoperative state any one or more of the following: ventricular tachycardia or fibrillation or
aborted sudden death, preoperative cardiac massage, preoperative ventilation
before arrival in the anaesthetic room, preoperative inotropic support,
intraaortic balloon counterpulsation or preoperative acute renal failure
(anuria or oliguriaB10 ml/hour)
3
Cardiac-related factors
Unstable angina rest angina requiring iv nitrates until arrival in the anaesthetic room 2
LV dysfunction moderate or LVEF30-50% 1
poor or LVEF B30 3
Recent myocardial infarct (B90 days) 2
Pulmonary hypertension Systolic PA pressure60 mmHg 2
Operation-related factors
Emergency carried out on referral before the beginning of the next working day 2
Other than isolated CABG major cardiac procedure other than or in addition to CABG 2
Surgery on thoracic aorta for disorder of ascending, arch or descending aorta 3
Postinfarction septal rupture 4
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